The Statistics and Data Center (SDC) of the Children's Oncology Group (COG) serve two important, distinct but related functions in COG. The first is to provide statistical sciences expertise in support of COG research through a staff of experienced Ph.D. level statisticians who are faculty members at major universities. These 'faculty' statisticians collaborate with COG investigators through their membership on COG study and scientific committees. They are assisted in this function by master-level statisticians and programmers who are also employed by the SDC. The second important function of the SDC is study and data operations - i.e., the coordination of COG research studies and the timely acquisition and storage of high quality data for COG studies, and interaction with COG institutions and study committees to ensure successful completion of COG studies. A staff of information technology professionals and research coordinators accomplish this SDC function. The COG SDC consist of two logically distinct departments or divisions: The first is the statistics department, which comprises the senior (Ph.D.) statisticians and assistant (M.S.) statisticians, plus some support staff. Although functioning as a united department, the members of this department are located at four main sites: The University of Southern California (USC)/Arcadia, the University of Nebraska/Omaha, the University of Florida/Gainesville and the University of Washington. The second division is data operations. This includes the Information Systems (IS) and computing staff which supports Remote Data Entry (RDE) and other necessary computing functions. All IS and computing staff will ultimately be located in Arcadia, although for the first two years of the grant period a small number will remain in Gainesville until the consolidation in Arcadia is complete. The division also includes a staff of research coordinators, who serve as the primary managers of studies and study data in the SDC, and who serve as the primary interface between the study committees, institutions, statisticians, the study development office and Group leadership, for all matters concerning data collection and related issues for ongoing COG studies. This staff is directed by a lead research coordinator who reports to the Group Statistician.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA098413-04
Application #
7013792
Study Section
Subcommittee G - Education (NCI)
Program Officer
Smith, Malcolm M
Project Start
2003-06-20
Project End
2008-02-29
Budget Start
2006-06-29
Budget End
2007-02-28
Support Year
4
Fiscal Year
2006
Total Cost
$6,066,063
Indirect Cost
Name
National Childhood Cancer Foundation
Department
Type
DUNS #
624124301
City
Arcadia
State
CA
Country
United States
Zip Code
91006
Agarwala, Sanjiv S; Lee, Sandra J; Yip, Waiki et al. (2017) Phase III Randomized Study of 4 Weeks of High-Dose Interferon-?-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Gro J Clin Oncol 35:885-892
Voigt, Andrew P; Brodersen, Lisa Eidenschink; Alonzo, Todd A et al. (2017) Phenotype in combination with genotype improves outcome prediction in acute myeloid leukemia: a report from Children's Oncology Group protocol AAML0531. Haematologica 102:2058-2068
Lee, Sanghoon; Day, Nancy S; Miles, Rodney R et al. (2017) Comparative genomic expression signatures of signal transduction pathways and targets in paediatric Burkitt lymphoma: a Children's Oncology Group report. Br J Haematol 177:601-611
Hardy, Kristina K; Embry, Leanne; Kairalla, John A et al. (2017) Neurocognitive Functioning of Children Treated for High-Risk B-Acute Lymphoblastic Leukemia Randomly Assigned to Different Methotrexate and Corticosteroid Treatment Strategies: A Report From the Children's Oncology Group. J Clin Oncol 35:2700-2707
Lim, Emilia L; Trinh, Diane L; Ries, Rhonda E et al. (2017) MicroRNA Expression-Based Model Indicates Event-Free Survival in Pediatric Acute Myeloid Leukemia. J Clin Oncol 35:3964-3977
Ermoian, Ralph P; Breneman, John; Walterhouse, David O et al. (2017) 45 Gy is not sufficient radiotherapy dose for Group III orbital embryonal rhabdomyosarcoma after less than complete response to 12 weeks of ARST0331 chemotherapy: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Pediatr Blood Cancer 64:
Liu, C; Yang, W; Pei, D et al. (2017) Genomewide Approach Validates Thiopurine Methyltransferase Activity Is a Monogenic Pharmacogenomic Trait. Clin Pharmacol Ther 101:373-381
Tasian, Sarah K; Teachey, David T; Li, Yong et al. (2017) Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood 129:177-187
Esbenshade, Adam J; Kocak, Mehmet; Hershon, Linda et al. (2017) A Phase II feasibility study of oral etoposide given concurrently with radiotherapy followed by dose intensive adjuvant chemotherapy for children with newly diagnosed high-risk medulloblastoma (protocol POG 9631): A report from the Children's Oncology Gro Pediatr Blood Cancer 64:
Taub, Jeffrey W; Berman, Jason N; Hitzler, Johann K et al. (2017) Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial. Blood 129:3304-3313

Showing the most recent 10 out of 438 publications